RBMY2FP

Across TCGA pan-cancer cohorts, RBMY2FP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RBMY2FP data layer compared with 12 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher RBMY2FP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMY2FP expression acts as an unfavorable survival marker.

LGG are the cancer types where RBMY2FP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.201	0.738	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RBMY2FP–LGG (DFS)

Open the LGG breakdown →